The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) (firmMIND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05429268
Recruitment Status : Recruiting
First Posted : June 23, 2022
Last Update Posted : June 6, 2024
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).

Condition or disease Intervention/treatment Phase
Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Drug: Tafasitamab Drug: Lenalidomide Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 81 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-arm, open-label, multicenter
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Actual Study Start Date : December 23, 2022
Estimated Primary Completion Date : December 24, 2025
Estimated Study Completion Date : December 24, 2026

Arm Intervention/treatment
Experimental: Tafasitamab and Lenalidomide
Tafasitamab and lenalidomide will be coadministered for up to 12 cycles (28 days per cycle).followed by tafasitamab monotherapy (in participants with stable disease or better) until treatment withdrawal criteria are met.
Drug: Tafasitamab
Tafasitamab will be administered intravenously in 28-day cycles. During Cycles 1 through 3, tafasitamab will be administered weekly on Days 1, 8, 15, and 22; an additional loading dose will be administered on Cycle 1 Day 4. Starting with Cycle 4, tafasitamab will be administered on Days 1 and 15 of each cycle.
Other Names:
  • INCMOR00208
  • MOR00208

Drug: Lenalidomide
Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 cycles.

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Approximately 24 months ]
    Percentage of participants having best response of Complete Response (CR) or Partial Response (PR) as per Independent Review Committee and investigator's assessment.

Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: Approximately 24 months ]
    Defined as the time from the first documented CR or PR until the date of first documented disease progression or death due to any cause, whichever occurs first, among participants who achieve CR or PR per Independent Review Committee (IRC) assessment and investigator's assessment.

  2. Progression Free Survial (PFS) [ Time Frame: Approximately 24 months ]
    Defined as the time from the date of first dose until the first documented disease progression, or death due to any cause, whichever occurs first per IRC assessment and investigator's assessment.

  3. Disease Control Rate (DCR) [ Time Frame: Approximately 24 months ]
    Defined as the percentage of participants who achieve CR, PR, or SD as per IRC assessment and investigator's assessment.

  4. Time to Next Treatment (TTNT) [ Time Frame: Approximately 24 months ]
    Defined as the time from first dose until the initiation of new anticancer therapy or death due to any reason, whichever occurs first.

  5. Overall Survival (OS) [ Time Frame: Approximately 24 months ]
    Defined as the time from the date of first dose until death due to any cause.

  6. Number of treatment-emergent adverse events [ Time Frame: Approximately 24 months ]
    Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment up to 90 days after last dose of study treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-confirmed diagnosis of any of the following:

    1. Diffuse large B-cell lymphoma not otherwise specified
    2. T cell/histiocyte-rich large B-cell lymphoma
    3. Epstein-Barr virus positive DLBCL of the elderly
    4. Grade 3b follicular lymphoma
    5. Composite lymphoma with a DLBCL component with a subsequent DLBCL relapse
    6. Evidence of histological transformation from an earlier diagnosis of low grade lymphoma (ie, an indolent pathology such as follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia) into DLBCL, with a subsequent DLBCL relapse
  • Willingness to undergo tumor biopsy requirements for the study, (or have archival lymph node or tissue block from the most recent biopsy, not to exceed 3 years prior to C1D1).
  • Willingness to undergo bone marrow biopsy/aspirate collections.
  • History of relapsed/progressive/recurrent disease according to the International Working Group response criteria after the most recent systemic therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Adequate hematologic, hepatic, and renal function,
  • Left ventricular ejection fraction (LVEF) ≥ 50%,
  • Willingness to avoid pregnancy or fathering children,

Exclusion Criteria:

  • Any other histological type of lymphoma according to the WHO 2016 classification of lymphoid neoplasms, including:

    1. primary mediastinal (thymic) large B-cell lymphoma,
    2. Burkitt lymphoma,
    3. Primary refractory diffuse large B-cell lymphoma (DLBCL),
    4. History of double- or triple-hit DLBCL.
  • Participants who, within 30 days prior to Cycle 1 Day 1, have:

    1. Not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma-specific therapy
    2. Undergone major surgery or suffered from significant traumatic injury
    3. Received live vaccines or have an anticipated need for such vaccination while receiving study treatment
    4. Required parenteral antimicrobial therapy for active, intercurrent infections
  • Have undergone ASCT within the period ≤ 3 months prior to signing consent.
  • Have undergone previous allogenic stem cell transplantation.
  • Inadequate recovery (> Grade 1) from prior treatment toxicity and/or complications from major surgery before Cycle 1 Day 1.
  • Have a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period.
  • Prior history of malignancies other than DLBCL, unless disease-free for ≥ 5 years prior to screening.
  • Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, New York Heart Association Class II to IV congestive heart failure, uncontrolled arrhythmia, and/or cardiac conduction issues, within 6 months of Cycle 1 Day 1.
  • Any of the following positive tests:

    1. Known seropositive for or history of active viral infection with HIV.
    2. Known positive test result for hepatitis C (HCV antibody serology testing) and a positive test result for HCV RNA.
    3. Known positive test results for chronic HBV infection (defined by HBsAg positivity). Participants with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA was undetectable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05429268

Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463
Contact: Incyte Corporation Call Center (ex-US) +800 00027423

Show Show 61 study locations
Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Study Director: Oliver Manzke, MD Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT05429268    
Other Study ID Numbers: INCMOR 0208-305
First Posted: June 23, 2022    Key Record Dates
Last Update Posted: June 6, 2024
Last Verified: June 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
Diffuse Large B-Cell Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents